| 000 | 01151 a2200277 4500 | ||
|---|---|---|---|
| 005 | 20250518075438.0 | ||
| 264 | 0 | _c20200826 | |
| 008 | 202008s 0 0 eng d | ||
| 022 | _a1437-4331 | ||
| 024 | 7 |
_a10.1515/cclm-2019-1065 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aUngerer, Jacobus P J | |
| 245 | 0 | 0 |
_aLetter in reply to the letter to the editor of Ferraro S and Panteghini M with the title "More robust analytical evidence should support the selection for human chorionic gonadotropin assays for oncology application". _h[electronic resource] |
| 260 |
_bClinical chemistry and laboratory medicine _c02 2020 |
||
| 300 |
_ae64-e65 p. _bdigital |
||
| 500 | _aPublication Type: Letter; Comment | ||
| 650 | 0 | 4 | _aBiological Assay |
| 650 | 0 | 4 | _aBiomarkers, Tumor |
| 650 | 0 | 4 | _aChorionic Gonadotropin |
| 650 | 0 | 4 | _aChorionic Gonadotropin, beta Subunit, Human |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMedical Oncology |
| 700 | 1 | _aPretorius, Carel J | |
| 773 | 0 |
_tClinical chemistry and laboratory medicine _gvol. 58 _gno. 3 _gp. e64-e65 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1515/cclm-2019-1065 _zAvailable from publisher's website |
| 999 |
_c30463423 _d30463423 |
||